Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Advanced NanotechROCO:6797 -0.90%56 Debt-to-Equity is 0.43 as of Jun. 2026, which is 16% above its 10-year median of 0.37. GuruFocus rates ROCO:6797 with a GF Score™ of 56/100 and a GF Value™ of NT$16.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 698 Medical Devices & Instruments companies, Taiwan Advanced Nanotech ranks worse than 65.76% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Taiwan Advanced Nanotech's Debt-to-Equity or its related term are showing as below:
ROCO:6797'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.37 Max: 0.67
Current: 0.43
During the past 9 years, the highest Debt-to-Equity Ratio of Taiwan Advanced Nanotech was 0.67. The lowest was 0.09. And the median was 0.37.
ROCO:6797's Debt-to-Equity is ranked worse than 65.76% of 698
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs ROCO:6797: 0.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Taiwan Advanced Nanotech Debt-to-Equity Related Terms
Taiwan Advanced Nanotech Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6797 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Taiwan Advanced Nanotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advanced Nanotech Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Advanced Nanotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Taiwan Advanced Nanotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advanced Nanotech (ROCO:6797) has a Debt-to-Equity of 0.43 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taiwan Advanced Nanotech and its competitors. This is 16% above median its historical median of 0.37. Over the past decade, Taiwan Advanced Nanotech's Debt-to-Equity has ranged from 0.09 to 0.67. According to the industry distribution chart, Taiwan Advanced Nanotech ranks #459 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Taiwan Advanced Nanotech's Debt-to-Equity too high?
Taiwan Advanced Nanotech's current Debt-to-Equity of 0.43 is 16% above median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.67. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Taiwan Advanced Nanotech's value of 0.43 is 79.2% above this industry median. Based on the distribution chart, Taiwan Advanced Nanotech ranks #459 out of 698 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Taiwan Advanced Nanotech has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advanced Nanotech's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Advanced Nanotech ranks #459 out of 698 companies for Debt-to-Equity. This places Taiwan Advanced Nanotech in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Taiwan Advanced Nanotech's value of 0.43 is 79.2% above this benchmark. Historically, Taiwan Advanced Nanotech's own Debt-to-Equity has ranged from 0.09 to 0.67 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 0.24, Taiwan Advanced Nanotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advanced Nanotech's current Debt-to-Equity of 0.43 is 79.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taiwan Advanced Nanotech and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advanced Nanotech's current Debt-to-Equity is 0.43, which is 16% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advanced Nanotech stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech (ROCO:6797) is currently considered Possible Value Trap. The stock's GF Value™ is NT$16.26, compared to a current price of NT$11.05 — trading 32% below its estimated fair value. The current Debt-to-Equity is 0.43, which is 16% above median its 10-year median of 0.37 and 79.2% above the Medical Devices & Instruments industry median of 0.24. Taiwan Advanced Nanotech's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Taiwan Advanced Nanotech (ROCO:6797), the current Debt-to-Equity is 0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advanced Nanotech (ROCO:6797) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech stock appears to be undervalued.
The current stock price of NT$11.05 is trading 32% below its estimated GF Value™ of NT$16.26.
GuruFocus considers Taiwan Advanced Nanotech to be Possible Value Trap.
Key valuation signals for ROCO:6797:
Debt-to-Equity: 0.43 (16% above median its 10-year median of 0.37)
GF Value™: NT$16.26 vs. price of NT$11.05 (32% below fair value)
Industry Position: 79.2% above the Medical Devices & Instruments median (#459 of 698)
No single metric tells the full story. See the ROCO:6797 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advanced Nanotech Inc is engaged in development and manufacturing of various functional nanoparticles and automated nucleic acid extraction machines and trading related businesses. With expertise in automation, buffer optimization and modification of magnetic beads, it focuses on offering customer convenient and practical solutions to advance research, life science and molecular diagnostics. It offers various products to meet the requirements of customers. The company's products include Automated Extraction Instruments; Reagent Kit; Mag Nanoparticles; and Consumables.
56GF Score
Get the complete analysis for ROCO:6797
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6797 has been successfully added to your 
